BR112017021669A2 - formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações - Google Patents

formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações

Info

Publication number
BR112017021669A2
BR112017021669A2 BR112017021669A BR112017021669A BR112017021669A2 BR 112017021669 A2 BR112017021669 A2 BR 112017021669A2 BR 112017021669 A BR112017021669 A BR 112017021669A BR 112017021669 A BR112017021669 A BR 112017021669A BR 112017021669 A2 BR112017021669 A2 BR 112017021669A2
Authority
BR
Brazil
Prior art keywords
formulations
crystals
treating diseases
oral pharmaceutical
pharmaceutical formulations
Prior art date
Application number
BR112017021669A
Other languages
English (en)
Inventor
Kesarwani Amit
Chaudhari Anita
Mathur Anoop
Dutt Chaitanya
Abraham Jaya
Kotecha Jignesh
Patel Manish
Chandra Gupta Ramesh
Latad Sachin
Deshpande Shailesh
Kumar Zambad Shital
Mishra Vivek
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of BR112017021669A2 publication Critical patent/BR112017021669A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

esta invenção refere-se a formulações farmacêuticas compreendendo 1-(2-tieno-2'-ila-2-oxo-etila)-3-(metanossulfonil hidrazina carbonila)piridínio, seus sais farmaceuticamente aceitáveis, co-cristais de sal e co-cristais, particularmente cloreto de 1-(2-tieno-2'-ila-2-oxo-etila)-3-(metanossulfonil hidrazina carbonila)piridínio. as formulações são adequadas para administração oral, e também compreendem um melhorador de permeabilidade ou uma base adequada, ou uma mistura destes. as formulações desta invenção servem para o tratamento de doenças associadas com produtos finais de glicação avançada.
BR112017021669A 2015-04-08 2016-04-05 formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações BR112017021669A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1475MU2015 2015-04-08
PCT/IB2016/051920 WO2016162787A1 (en) 2015-04-08 2016-04-05 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
BR112017021669A2 true BR112017021669A2 (pt) 2018-07-10

Family

ID=55808800

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017021669A BR112017021669A2 (pt) 2015-04-08 2016-04-05 formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações

Country Status (30)

Country Link
US (1) US10772879B2 (pt)
EP (1) EP3280447B1 (pt)
JP (1) JP6736656B2 (pt)
KR (1) KR20170134662A (pt)
CN (1) CN107530287B (pt)
AR (1) AR104185A1 (pt)
AU (1) AU2016246124B2 (pt)
BR (1) BR112017021669A2 (pt)
CA (1) CA2997463A1 (pt)
CY (1) CY1121921T1 (pt)
DK (1) DK3280447T3 (pt)
EA (1) EA037041B1 (pt)
ES (1) ES2724629T3 (pt)
HR (1) HRP20190783T1 (pt)
HU (1) HUE044889T2 (pt)
IL (1) IL254794B (pt)
LT (1) LT3280447T (pt)
MX (1) MX2017012942A (pt)
MY (1) MY182008A (pt)
PH (1) PH12017501829A1 (pt)
PL (1) PL3280447T3 (pt)
PT (1) PT3280447T (pt)
RS (1) RS58708B1 (pt)
SG (1) SG11201708142XA (pt)
SI (1) SI3280447T1 (pt)
TR (1) TR201906476T4 (pt)
TW (1) TWI713512B (pt)
UA (1) UA123051C2 (pt)
WO (1) WO2016162787A1 (pt)
ZA (1) ZA201707094B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3169368A1 (en) 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
EP3888642A1 (en) 2013-03-22 2021-10-06 Nova Southeastern University Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
CA3116730A1 (en) * 2018-10-19 2020-04-23 Nova Southeastern University Sublingual epinephrine compositions including ph-modifying excipients and penetration enhancers and methods for use thereof
KR102330597B1 (ko) * 2020-04-17 2021-11-26 보령제약 주식회사 무정형의 엠파글리플로진을 포함하는 안정성이 향상된 신규 약제학적 제형

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE386508T1 (de) * 1999-02-22 2008-03-15 Merrion Res I Ltd Feste orale dosierungsform enthaltend einen resorptionsverstärker
PT1222171E (pt) * 1999-10-06 2004-07-30 Torrent Pharmaceuticals Ltd Derivados do piridinio para o tratamento das doencas vasculares relacionadas com o envelhecimento e a diabetes e processo para a sua preparacao e utilizacao terapeutica destes derivados
ES2243389T3 (es) 2001-03-21 2005-12-01 Torrent Pharmaceuticals Ltd Compuestos de piridinio utiles para el tratamiento de enfermedades relacionadas con los age.
MX2008011227A (es) 2006-03-03 2009-02-10 Torrent Pharmaceuticals Ltd Receptores antagonistas de accion nueva y doble en los receptores at1 y eta.
JP2009023932A (ja) * 2007-07-18 2009-02-05 Tama Tlo Kk Ｎ−メチルピリジニウム化合物を有効成分として含有する抗ウイルス剤、それを含有する、抗ウイルス組成物、食餌及び動物用飼料
BRPI0907650A2 (pt) * 2008-01-25 2015-07-21 Torrent Pharmaceuticals Ltd Composições farmacêuticas compreendendo degradadores de produtos finais de glicosilação avançada (ages) e drogas adjuvantes como drogas anti-hipertensivas, antidiabéticas e etc
CN101574343B (zh) * 2008-05-07 2011-06-01 吉林大学 一种治疗糖尿病的药物组合物
WO2010128528A2 (en) * 2009-05-07 2010-11-11 Torrent Pharmaceuticals Limited Novel heterocyclic compounds
JP2013514976A (ja) * 2009-12-16 2013-05-02 ノッド ファーマシューティカルズ， インコーポレイテッド 経口薬物送達のための組成物および方法
CN104069066B (zh) * 2013-03-25 2017-04-19 吉林大学 黄癸固体分散体及其在治疗糖尿病及并发症中的应用

Also Published As

Publication number Publication date
MY182008A (en) 2021-01-18
TR201906476T4 (tr) 2019-05-21
RS58708B1 (sr) 2019-06-28
CY1121921T1 (el) 2020-10-14
AR104185A1 (es) 2017-07-05
PT3280447T (pt) 2019-05-14
AU2016246124B2 (en) 2019-11-14
EA037041B1 (ru) 2021-01-29
IL254794A0 (en) 2017-12-31
MX2017012942A (es) 2018-01-30
US10772879B2 (en) 2020-09-15
TW201642858A (zh) 2016-12-16
CN107530287A (zh) 2018-01-02
JP6736656B2 (ja) 2020-08-05
SG11201708142XA (en) 2017-11-29
UA123051C2 (uk) 2021-02-10
US20180110763A1 (en) 2018-04-26
HRP20190783T1 (hr) 2019-06-28
IL254794B (en) 2021-05-31
PH12017501829A1 (en) 2018-04-23
ES2724629T3 (es) 2019-09-12
JP2018510916A (ja) 2018-04-19
AU2016246124A1 (en) 2017-11-02
WO2016162787A1 (en) 2016-10-13
CA2997463A1 (en) 2016-10-13
EP3280447A1 (en) 2018-02-14
DK3280447T3 (da) 2019-05-13
HUE044889T2 (hu) 2019-11-28
ZA201707094B (en) 2021-04-28
EA201792237A1 (ru) 2018-02-28
LT3280447T (lt) 2019-05-27
SI3280447T1 (sl) 2019-06-28
PL3280447T3 (pl) 2019-07-31
CN107530287B (zh) 2020-11-10
TWI713512B (zh) 2020-12-21
EP3280447B1 (en) 2019-02-27
KR20170134662A (ko) 2017-12-06

Similar Documents

Publication Publication Date Title
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
UA122346C2 (uk) ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
MY187047A (en) Selective pyy compounds and uses thereof
BR112017005736A2 (pt) macrociclos peptidomiméticos e formulações dos mesmos
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
EA201892119A1 (ru) Лекарственный препарат, полученный путем комбинирования агониста fxr и arb
BR112017021669A2 (pt) formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
EA201692298A1 (ru) Производные карбоксамидов
BR112019000897A2 (pt) sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão.
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок
BR112019000509A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements